Abstract
Coronavirus disease 2019 (COVID-19) remains a major health challenge globally. Previous studies have suggested that changes in the glycosylation of IgG are closely associated with the severity of COVID-19. This study aimed to compare the profiles of IgG N-glycome between COVID-19 patients and healthy controls. A case-control study was conducted, in which 104 COVID-19 patients and 104 age- and sex-matched healthy individuals were recruited. Serum IgG N-glycome composition was analyzed by hydrophilic interaction liquid chromatography with the ultra-high-performance liquid chromatography (HILIC-UPLC) approach. COVID-19 patients have a decreased level of IgG fucosylation, which upregulates antibody-dependent cell cytotoxicity (ADCC) in acute immune responses. In severe cases, a low level of IgG sialylation contributes to the ADCC-regulated enhancement of inflammatory cytokines. The decreases in sialylation and galactosylation play a role in COVID-19 pathogenesis via the activation of the lectin-initiated alternative complement pathway. IgG N-glycosylation underlines the complex clinical phenotypes of SARS-CoV-2 infection.
Document Type
Journal Article
Date of Publication
2021
Publication Title
Frontiers in Immunology
Publisher
Frontiers Media S.A.
School
School of Medical and Health Sciences
RAS ID
37014
Funders
Edith Cowan University - Open Access Support Scheme 2021
National Health and Medical Research Council
National Natural Science Foundation of China
China-Australia International Collaborative Grant
European Commission Horizon 2020 Framework Program
Grant Number
NHMRC Number : APP1112767
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Comments
Hou, H., Yang, H., Liu, P., Huang, C., Wang, M., Li, Y., . . . Wang, W. (2021). Profile of immunoglobulin G N-glycome in COVID-19 patients: A case-control study. Frontiers in Immunology, 12, article 748566. https://doi.org/10.3389/fimmu.2021.748566